Chronic and Refractory Laminitis: Why the Unmet Need Drives Research

Chronic equine laminitis is not a niche problem. It is among the most common causes of long-term disability in horses and ponies, and a leading reason for euthanasia on welfare grounds in many countries. Despite decades of clinical and scientific effort, management remains largely supportive, and for a meaningful proportion of affected animals, no current intervention prevents ongoing structural deterioration. This article examines what distinguishes chronic and refractory cases, why existing tools are insufficient, and why that gap underpins the scientific rationale for investigational research programmes including PTP-102.

Internal links: For the pathophysiology underlying these cases, see What Is Equine Laminitis? A Scientific Overview of Lamellar Pathophysiology. For clinical staging, see Recognising Laminitis: Clinical Signs, Obel Grading and What Each Stage Tells Vets. For current treatment options and their evidence, see Current Treatment Options for Equine Laminitis: Evidence, Limitations and Gaps.

Defining Chronic Laminitis

In clinical usage, laminitis is described as chronic when:

1. Radiographic evidence of structural change — rotation or displacement of the distal phalanx — is present, or

2. Clinical signs of active pain or lameness persist beyond approximately 72 hours without resolution, or

3. A horse experiences repeated episodes of acute disease, with incomplete resolution between events.

The distinction between chronic and acute disease is not always sharp, and individual horses may present anywhere along a continuum from low-grade persistent discomfort to severely disabling ongoing disease.

Refractory chronic laminitis describes cases that fail to stabilise with appropriate standard care: analgesic management, mechanical support, dietary modification, and treatment of any underlying endocrine or infectious trigger. These horses represent both the most severe welfare challenge and the clinical population where new treatment approaches are most needed.

Epidemiology: Scale of the Problem

Precise prevalence data for equine laminitis are difficult to obtain, but several large-scale surveys give a useful indication:

• A 2011 UK-based survey of owners and veterinarians estimated laminitis prevalence at approximately 7–8% in the general equine population, with higher rates in certain breeds and management systems (Wylie et al., Equine Veterinary Journal, 2013).

• Laminitis is consistently among the top three causes of death and euthanasia in horses and ponies in survey data from the UK and North America.

• The condition disproportionately affects ponies, native breeds, and horses with EMS or PPID — populations that are growing as equine demographics shift toward recreational use and older animals.

These figures represent horses with documented episodes; subclinical chronic lamellar change without acute presentation may be more common than survey data suggest.

Why Chronic Cases Are Difficult to Manage

The Structural Damage Problem

Once the lamellar interface has undergone significant structural failure — with rotation or displacement of the distal phalanx — the mechanical loading of the hoof changes permanently. Corrective shoeing and trimming can partially compensate, but they cannot reconstitute the anatomy. The result is that many chronic horses require lifelong, specialised farriery to remain comfortable, and their tolerance for exercise is permanently reduced.

The Inflammatory Perpetuation Problem

In some chronic cases, low-grade inflammation within the lamellar tissue appears to perpetuate ongoing damage even after the initial triggering event has been resolved. The mechanisms maintaining this inflammatory state are not fully characterised, and current anti-inflammatory strategies — primarily NSAIDs — provide symptomatic relief without addressing the underlying tissue process.

The Endocrine Complication

For the large proportion of horses whose laminitis is endocrinopathic, long-term management requires sustained control of insulin dysregulation and, where PPID is present, pituitary-targeted therapy. These interventions reduce recurrence risk but do not reverse established lamellar damage. Compliance, cost and individual horse variability all limit their effectiveness in practice.

The Pain Management Ceiling

Long-term NSAID use carries gastrointestinal and renal risks. In horses with refractory chronic laminitis, the need for sustained analgesia creates a clinical dilemma: insufficient pain control compromises welfare, while prolonged high-dose NSAID use creates its own risks. No approved analgesic agent specifically designed for chronic lamellar pain management exists.

What "Disease-Modifying" Would Mean

A disease-modifying treatment for laminitis would need to do at least one of the following:

1. Reduce lamellar tissue injury during the developmental or acute phase, preventing structural damage from establishing in the first place.

2. Arrest ongoing lamellar damage in chronic cases where active inflammation is perpetuating deterioration.

3. Support tissue repair or remodelling — reducing the long-term mechanical consequences of established structural change.

No currently approved veterinary product has demonstrated any of these effects in controlled clinical trials. The closest approach to point 1 is cryotherapy during the developmental phase, which has reasonable experimental evidence but is not pharmacological.

This gap is precisely what drives continued research into novel therapeutic approaches, including compounds explored in preclinical and experimental animal studies such as the PTP-102 investigational programme.

The Research Rationale for PTP-102

Investigational programmes targeting equine laminitis — including PTP-102 — are motivated by the specific insufficiencies above. Byrock Technologies Ltd is developing PTP-102 as an investigational veterinary product, and the scientific rationale begins with these unmet needs.

It is important to state clearly: the existence of an unmet need does not itself demonstrate that any investigational compound will fill it. The studies conducted to date on PTP-102 are exploratory and experimental in nature. They provide a basis for continued investigation; they do not establish clinical efficacy or safety in naturally occurring equine laminitis.

Readers evaluating the PTP-102 evidence base should approach it with the same critical framework they would apply to any preclinical programme: asking what each study was designed to measure, what the data actually show, and what further evidence would be required to support any regulatory or clinical claim.

Summary

• Chronic laminitis affects a substantial proportion of the equine population and is a leading welfare and euthanasia concern.

• Refractory cases — where standard management fails to halt progression — represent the most severe unmet clinical need.

• No approved pharmacological agent has demonstrated disease-modifying efficacy in controlled trials.

• These gaps define the scientific and commercial context for investigational research, including PTP-102, which remains at an exploratory stage.

This article is intended for equine veterinary professionals and researchers. Epidemiological estimates cited reflect published survey data and are provided for context, not as precision prevalence figures. PTP-102 is an investigational product and has not been approved by any regulatory authority.

Content notice: This article was prepared with AI assistance by the Byrock Editorial Team and has not been independently verified by an external consultant, regulatory authority, or peer reviewer. It does not represent the position of any regulatory body. Readers are encouraged to consult primary sources and qualified specialists.